Background Benefit of thrombolytic therapy in patients with massive pulmonary embolism
(PE) is evident. However, evidence supporting benefit in clinical outcomes of this approach …

Background The use of thrombolysis in patients with acute, intermediate-risk pulmonary
embolism (PE) remains controversial. This meta-analysis compared the efficacy and safety …

Background The use of thrombolytic therapy in patients with intermediate-risk pulmonary
embolism is controversial. To compare with anticoagulation alone, no analysis before has …

Background: Trial sequential analysis (TSA) is a technique used to establish the threshold
when firm evidence is reached in meta-analyses. We performed a TSA of randomized …

Purpose The aim of this systematic review was to evaluate the efficacy and safety of
thrombolytic treatment in patients with submassive pulmonary embolism (PE). Methods An …

BACKGROUND: Randomized trials and meta-analyses have reached conflicting
conclusions regarding the risk benefit ratio of thrombolytic therapy or anticoagulant therapy …

Abstract Background Randomized controlled trials (RCTs) comparing systemic thrombolysis
to anticoagulation in intermediate risk pulmonary embolism (PE) have yielded mixed results …

Current guidelines recommend anticoagulation (AC) for low and intermediate-risk
pulmonary embolism (PE) and systemic thrombolysis (tPA) for high risk (massive) PE. How …

Purpose Current literature on clinical controversies surrounding the use of thrombolytic
agents in patients with intermediate-risk pulmonary embolism (PE) is reviewed. Summary …

Background: Pulmonary emboli (PE) represents an extended spectrum of diseases. 10% of
submassive PE progress to massive PE, and while overall mortality is around 5%, it can …